Skip to main content

Lepu Biopharma

Lepu Biopharma Co Ltd is a Chinese clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing targeted cancer therapeutics and immuno-oncology drugs. The company develops antibody-drug conjugates (ADCs), monoclonal antibodies, and cancer vaccines, including Puyonik (puyonitimab) for advanced solid tumors and clinical ADC candidates targeting EGFR and CLDN18.2. Principal revenues derive from commercial sales of approved oncology drugs, upfront licensing payments, and research collaboration fees with global biopharmaceutical partners. Core end markets encompass medical oncology clinics, clinical trial hospital centers, and prescription cancer patients across China and international markets. Lepu Biopharma holds an innovative position in China's biopharmaceutical industry as a specialized developer of antibody-drug conjugate oncology therapies. The company is headquartered in Shanghai, China, and its shares trade on the Stock Exchange of Hong Kong.

2 of the funds FundTelligence covers report a position in Lepu Biopharma.

Legal name
Lepu Biopharma Co Ltd
Sector
Health Care
Country
China
Funds holding it
2

Funds holding Lepu Biopharma

Loading...